25 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 25 separate news trends connected to Biotech, spanning June 23, 2026 through August 22, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 213 article observations and 203 source signals, led by Business, Health, Science coverage. Use it to compare how individual events emerged, spread and changed over time.
Moderna and Merck see a massive market surge following successful phase 3 clinical trial results for a personalized melanoma vaccine.
A drug designed to mimic exercise has passed its first human trial, sparking interest in the medical community.
Amylyx Pharmaceuticals' stock surges after a GLP-1 antagonist drug shows promise in a new application.
EyePoint Pharmaceuticals' stock plummets after a clinical trial setback, leaving investors reeling and analysts divided.
Scientists are racing to build AI-driven digital organisms to test drugs before human trials
Capricor Therapeutics' stock surges on news of a potential FDA lifeline for its Duchenne muscular dystrophy drug.
The RK Mellon Foundation's $25M investment aims to transform Pittsburgh into a hub for rare disease therapies.
Boulevard Bio debuts with $65 million in funding to advance a pipeline of targeted antibody therapies focused on autoimmune disease.
Research indicates AI integration could deliver 82 times the return on investment in oncology clinical trials while reshaping the drug development market.
Alameda-based biotech Infinimmune has secured $75 million in Series A funding to advance its antibody pipeline for atopic dermatitis and inflammatory diseases.
Since August 10, 2026, a triple-dose regimen has shown promise in permanently clearing HIV in infected newborns.
AbCellera's stock surged after its drug showed promise in treating menopause hot flashes.
LifeMine Therapeutics has secured a massive investment from tech giants Bill Gates and Jeff Bezos, despite conflicting reports on the amount raised.
Kindred Companion Sciences has unveiled the world's first beagles genetically edited via CRISPR to remove the protein responsible for triggering dog allergies.
An FDA advisory committee has voted 10-3 in favor of Replimune’s oncolytic immunotherapy for melanoma, marking a turning point for the twice-rejected treatment.
7 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
8 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Danaher shares are sliding despite a second-quarter earnings beat and raised guidance, driven by a "surprisingly soft" business unit.
Prediction platform Kalshi is launching sports-style betting markets focused on biotech clinical trials and FDA drug approvals.
Celcuity stock fell by double digits despite securing its first FDA approval for a new breast cancer treatment.
Biogen’s experimental tau-targeting Alzheimer’s drug sparks industry debate following mixed clinical trial results.
Novo Nordisk has entered into a partnership with Vivani to develop a long-acting semaglutide implant designed for weight management.
Novartis is expanding its antibody-drug conjugate (ADC) pipeline through the acquisition of U.K.-based cancer biotech Myricx Bio for up to $1.5 billion.
French biotech company Ipsen is acquiring Kartos Therapeutics for up to $1.75 billion to expand its blood cancer pipeline.
Sangamo Therapeutics' bankruptcy filing and asset sale to Lilly and Astellas is making waves in the biotech industry.